Bridging Two Modalities: Explore How Dual-Precision Targeted Protein Degradation (TPD2) Enables Cell-Specific GSPT1 Degradation for Potent Antitumor Activity
- Discover how Orum’s TPD² platform fuses antibody targeting with catalytic protein degradation to deliver potent activity against undruggable intracellular targets
- Discuss ORM-1153, a CD123-targeting Degrader Antibody Conjugate (DAC) with a novel GSPT1-degrading payload, with the aim of achieving selective delivery to AML blasts and inducing cytotoxicity via GSPT1 degradation
- Outline the proprietary linker technology used to enable the stable conjugation and subsequent traceless, intracellular release of the TPD payloads from the antibody